Literature DB >> 15592025

Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract.

Yasuyoshi Miyata1, Shigeru Kanda, Koichiro Nomata, Jiro Eguchi, Hiroshi Kanetake.   

Abstract

PURPOSE: Prostaglandin E2, produced by cyclooxygenase (COX)-2, affects the behavior of tumor cells possibly through 1 of the prostaglandin E2 receptors, the EP4 receptor (EP4R). The relationship between tumor development and EP4R in transitional cell carcinoma of the upper urinary tract (TCC-UUT) has not been fully understood. We determined the relationships between clinicopathological features and prognosis with expressions of COX-2 and EP4R in nonmetastatic TCC-UUT.
MATERIALS AND METHODS: We examined expressions of COX-2 and EP4R by immunohistochemical technique in 101 patients. Histological features including tumor grade, pT stage and lymph node metastasis were examined using formalin fixed and paraffin embedded specimens from the radical operation. The predictive values of these expressions of prognosis were investigated by Kaplan-Meier curve and Cox proportional hazards analysis in multivariate model.
RESULTS: Expression of COX-2 and EP4R was observed in 46 (45.5%) and 51 (50.5%) cases, respectively. Each expression was significantly associated with pT stage and grade. Patients with co-expression of these proteins had a higher frequency of extra-urinary tract recurrence (33.3%). Postoperative survival time of patients with co-expression of COX-2 and EP4R was significantly shorter than that of patients with other expression patterns (p <0.001). Although COX-2 or EP4R expression was not an independent factor for cause specific survival in a multivariate model, co-expression of these proteins was an independent one (odds ratio 12.26 and p = 0.0038).
CONCLUSIONS: Co-expression of COX-2 and EP4R is a potentially useful marker for tumor progression and survival in patients with nonmetastatic TCC-UUT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15592025     DOI: 10.1097/01.ju.0000148272.77539.2d

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

Review 1.  Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.

Authors:  Aurélie Mbeutcha; Morgan Rouprêt; Ashish M Kamat; Pierre I Karakiewicz; Nathan Lawrentschuk; Giacomo Novara; Jay D Raman; Christian Seitz; Evanguelos Xylinas; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-04-21       Impact factor: 4.226

2.  Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study.

Authors:  Vincenzo Pagliarulo; Patrizia Ancona; Ivan Martines; Rossana Spadavecchia; Savino Di Stasi; Stefano Alba; Luigi Cormio; Caterina Fanizza; Annamaria Salerno; Giuseppe Carrieri; Arcangelo Pagliarulo
Journal:  Ther Adv Urol       Date:  2015-12

3.  Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.

Authors:  Laura von der Emde; Diane Goltz; Stefan Latz; Stefan C Müller; Glen Kristiansen; Jörg Ellinger; Isabella Syring
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

4.  Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract.

Authors:  Yasuyoshi Miyata; Kojiro Ohba; Shigeru Kanda; Koichiro Nomata; Jiro Eguchi; Tomayoshi Hayashi; Hiroshi Kanetake
Journal:  Virchows Arch       Date:  2006-04-12       Impact factor: 4.064

5.  Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function.

Authors:  Namita Kundu; Xinrong Ma; Dawn Holt; Olga Goloubeva; Suzanne Ostrand-Rosenberg; Amy M Fulton
Journal:  Breast Cancer Res Treat       Date:  2008-09-16       Impact factor: 4.872

Review 6.  Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature.

Authors:  Aurélie Mbeutcha; Romain Mathieu; Morgan Rouprêt; Kilian M Gust; Alberto Briganti; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Transl Androl Urol       Date:  2016-10

Review 7.  E-type prostanoid receptor 4 (EP4) in disease and therapy.

Authors:  Viktoria Konya; Gunther Marsche; Rufina Schuligoi; Akos Heinemann
Journal:  Pharmacol Ther       Date:  2013-03-21       Impact factor: 12.310

8.  The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line.

Authors:  Vincenzo Pagliarulo; Patrizia Ancona; Mauro Niso; Nicola Antonio Colabufo; Marialessandra Contino; Luigi Cormio; Amalia Azzariti; Arcangelo Pagliarulo
Journal:  Mol Cancer       Date:  2013-05-24       Impact factor: 27.401

9.  Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma.

Authors:  S Yoshimine; E Kikuchi; T Kosaka; S Mikami; A Miyajima; Y Okada; M Oya
Journal:  Br J Cancer       Date:  2013-05-14       Impact factor: 7.640

10.  Impact of caveolin-1 expression on the prognosis of transitional cell carcinoma of the upper urinary tract.

Authors:  Dae Sung Cho; Hyunee Yim; Kang Su Cho; Sung Joon Hong; Nam Hoon Cho; Sun Il Kim; Hyun Soo Ahn; Se Joong Kim
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.